Author(s)

Shaima Al-Bader¹, Kamel El-Reshaid^2*

¹Asad Al-Hamad Dermatology Center, Kuwait.
²Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait.

Background: Idiopathic Bullous Pemphigoid (IBP) is a rare blistering autoimmune disease. Its morbidity and mortality have remained high owing to complications of extensive skin involvement as well as its conventional steroid therapy. We reviewed the medical literature and found indicators of an autoimmune etiology for its pathogenesis triggering genetically predisposed patients. Objective: to evaluate, prospectively, the role of Rituximab (R) therapy in its persistent, severe and extensive form. Patients and methods: A total of 12 patients, with disease duration of 6 ± 1 months, were treated with yearly R infusions (1 g followed by 1 g 2 weeks later). Results: Significant clinical improvement was achieved as documented by decrease in total score of Bullous Pemphigoid Disease Area Index from 60 ± 3 to 6 ± 2 that persisted for 26 ± 11 months of follow up. Moreover, IBP autoantibodies (anti-BP 180 and anti-320 IgG) levels fell from to 91 ± 3 and 81 ± 2 to 8 ± 2 and 9 ± 2, respectively. Conclusions: R is a safe and effective treatment for severe IBP and such response further confirms its autoimmune pathogenesis.

Bullous Pemphigoid, Rituximab, Treatment, BP Autoantibodies, Bullous Pemphigoid Disease Area Index

Al-Bader, S. and El-Reshaid, K. (2023) Rituximab Therapy for Persistent, Severe and Extensive Idiopathic Bullous Pemphigoid. Journal of Cosmetics, Dermatological Sciences and Applications, 13, 76-83. doi: 10.4236/jcdsa.2023.131008.